<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>HER2 and predicting response to therapy in breast cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">HER2 and predicting response to therapy in breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">HER2 and predicting response to therapy in breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hideko Yamauchi, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ira J Bleiweiss, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Breast cancer is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior. Amplification or overexpression of the human epidermal growth factor receptor 2 (<em>HER2</em>) oncogene is present in approximately 15 percent of primary invasive breast cancers [<a href="#rid1">1</a>]. Women with both early-stage and metastatic breast cancer that meet criteria for HER2 positivity are treated with regimens including HER2-directed therapy. </p><p>Here we will review the definition of HER2 positivity, and the approach to <em>HER2</em> discordance. Management of those with HER2-positive disease in the neoadjuvant, adjuvant, and metastatic settings, as well as treatment protocols for HER2-positive breast cancer, are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/106774.html" rel="external">"Neoadjuvant therapy for patients with HER2-positive breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85677.html" rel="external">"Treatment protocols for breast cancer", section on 'Regimens for HER2-positive breast cancer'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">THE HER2 ONCOGENE</span><span class="headingEndMark"> — </span>The <em>HER2</em> oncogene encodes for a 185 KD transmembrane glycoprotein receptor with intracellular tyrosine kinase activity [<a href="#rid1">1</a>]. The HER2 receptor belongs to the epidermal growth factor receptor (EGFR) family of receptors, which are critical in the activation of subcellular signal transduction pathways controlling epithelial cell growth and differentiation [<a href="#rid2">2,3</a>] and possibly angiogenesis [<a href="#rid4">4,5</a>]. HER2, the epidermal growth factor receptor 2, was previously called HER2/neu, or ERBB-2.</p><p class="headingAnchor" id="H3"><span class="h2">Clinical utility of HER2 testing</span><span class="headingEndMark"> — </span>Because HER2 status is a predictive factor in breast cancer, we recommend routine testing of HER2 expression on newly diagnosed, invasive, and metastatic breast cancers, in accordance with several guideline bodies [<a href="#rid6">6-10</a>]. High levels of HER2 expression identify those women who benefit from treatment with agents that target HER2.</p><p>HER2 overexpression was associated with high rates of disease recurrence and death in the absence of adjuvant systemic therapy. However, the value of this prognostic information in clinical practice is questionable, particularly with the earlier use of HER2-directed agents in the neoadjuvant and adjuvant setting.</p><p>For women with hormone receptor-positive breast cancer, HER2 gene expression is an important component of the 21-gene recurrence score assay. (See  <a class="medical medical_review" href="/z/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">TESTING FOR HER2 EXPRESSION</span><span class="headingEndMark"> — </span>There are many ways to measure the activity of the HER2 oncogene; the best method, both in terms of the type of assay used and the optimal way to perform each type of assay, is controversial. The assays used clinically are below:</p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression of the HER2 protein product – Western blotting, enzyme-linked immunosorbent assay (ELISA), or immunohistochemistry (IHC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HER2 gene amplification by in situ hybridization (ISH) – Fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), silver-enhanced in situ hybridization (SISH), or differential polymerase chain reaction (PCR).</p><p></p><p class="headingAnchor" id="H3657637196"><span class="h2">IHC and ISH</span><span class="headingEndMark"> — </span>The majority of patients who test positive for <em>HER2</em> should receive HER2-directed therapy.</p><p>We agree with the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines for HER2 testing, which are summarized in the table (<a class="graphic graphic_table graphicRef75536" href="/z/d/graphic/75536.html" rel="external">table 1</a>) [<a href="#rid8">8,10</a>].</p><p>In general, we obtain immunohistochemistry (IHC) in cases of newly diagnosed, invasive breast cancer or recurrence, and obtain in situ hybridization (ISH) for IHC 2+. The interpretation of IHC and FISH testing of breast tumors is discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span>HER2 testing should be performed on the invasive component using a validated IHC or ISH assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IHC staining is defined as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IHC 3+ if there is complete and intense circumferential membrane staining within &gt;10 percent of tumor cells. <strong>All IHC 3+ tumors are considered HER2 positive. </strong>(See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IHC 2+ if there is incomplete and/or weak/moderate, circumferential membrane staining within &gt;10 percent of tumor cells. All IHC 2+ tumors are reported as HER2 equivocal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IHC 1+ if there is faint or barely perceptible, incomplete membrane staining within &gt;10 percent of tumor cells. All IHC 1+ tumors are reported as HER2 negative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IHC 0 if (1) no staining is observed, or (2) there is faint or barely perceptible, incomplete membrane staining within &lt;10 percent of tumor cells. All IHC 0 tumors are reported as HER2 negative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Equivocal HER2 testing should trigger reflex HER2 testing using ISH on the same specimen or a new test (using a different specimen with either IHC or ISH). Alternative genomic tests are not recommended for routine use, as they have not been clinically validated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Results from ISH are defined as the ratio of gene amplification of <em>HER2</em> and the chromosome 17 enumeration probe (CEP17). Results are reported as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ISH<strong> positive</strong> if the <strong><em>HER2</em></strong><strong>/CEP17 ratio is ≥2.0</strong>, and <strong>the </strong><strong><em>HER2</em></strong><strong> copy number signals/cell is ≥4</strong>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Definitive diagnosis will be rendered pending further workup in the following instances (<a class="graphic graphic_table graphicRef118704" href="/z/d/graphic/118704.html" rel="external">table 2</a>) [<a href="#rid11">11</a>]:</p><p></p><p class="bulletIndent3">1) If the <em>HER2</em>/CEP17 ratio is ≥2.0 and an average <em>HER2</em> copy number is &lt;4.0 signals/cell.</p><p></p><p class="bulletIndent3">2) If the <em>HER2</em>/CEP17 ratio is &lt;2.0 and the average <em>HER2</em> copy number is ≥6.0 signals/cell.</p><p></p><p class="bulletIndent3">3) If the <em>HER2</em>/CEP17 ratio is &lt;2.0 and an average <em>HER2</em> copy number is between ≥4.0 and &lt;6.0 signals/cell.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ISH <strong>negative</strong> if the <em>HER2</em>/CEP17 ratio is &lt;2.0 and average <em>HER2</em> copy number is &lt;4.0 signals/cell.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specimens should be processed quickly (time to fixation within one hour) using 10 percent neutral buffered formalin for 6 to 72 hours. Reporting should incorporate these times.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Situations in which to retest</span><span class="headingEndMark"> — </span>The ASCO/CAP update suggests repeat testing of patients with newly diagnosed breast cancer if histopathologic features are present suggesting HER2 discordance [<a href="#rid8">8,10</a>].</p><p>In summary, repeat HER2 testing should be performed if:</p><p class="bulletIndent1"><span class="glyph">●</span>The initial test was HER2-positive in a histologic grade 1 carcinoma of the following types:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infiltrating ductal or lobular carcinoma, hormone receptor-positive.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any of the following histologies, all of which at least 90 percent pure: mucinous, cribriform, tubular, or adenoid cystic.</p><p></p><p>The 2018 ASCO/CAP update notes that repeat HER2 testing <strong>may</strong> be performed in the following instances:</p><p class="bulletIndent1"><span class="glyph">●</span>The test was HER2-negative in a tumor exhibiting any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Grade 3 differentiation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The invasive component was small (if initial testing was performed on biopsy material).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoma at definitive resection contains a high-grade carcinoma morphologically distinct from that in the original biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The core biopsy result was equivocal by both IHC and ISH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is doubt about the specimen handling, or testing error is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2013 ASCO/CAP guidelines recommend that HER2 status be reanalyzed on a repeat biopsy sample in patients who present with recurrent or metastatic breast cancer [<a href="#rid8">8</a>], given that the level of discordance in HER2 status in paired primary and metastatic breast cancers ranges between 2 and 25 percent [<a href="#rid12">12-15</a>]. A substantial proportion of women with HER2-negative primary tumors acquired protein overexpression when their tumors recurred [<a href="#rid15">15-18</a>].</p><p></p><p class="headingAnchor" id="H3546088760"><span class="h2">No indication for assessment of circulating HER2 ECD</span><span class="headingEndMark"> — </span>The clinical utility of assessing or following circulating HER2 protein extracellular domain (c-ECD) levels during HER2-directed therapy is not established. The ASCO expert panel on tumor markers in breast cancer recommended against the use of serum c-ECD in any clinical setting [<a href="#rid19">19</a>].</p><p>Multiple studies have addressed whether circulating HER2 c-ECD predicts response to HER2-directed treatment, with conflicting results [<a href="#rid20">20-23</a>]. For example, in a pooled analysis of seven trials of first-line <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> with or without chemotherapy, patients with a 20 percent or greater decline in c-ECD levels over baseline had significantly higher response rates to trastuzumab (57 versus 28 percent) as well as significantly longer time to progression and overall survival compared with those with a lesser degree of decline [<a href="#rid23">23,24</a>]. However, a separate review of 63 studies concluded that concentrations of HER2 ECD are not consistently related to patient outcomes [<a href="#rid25">25</a>].</p><p>Other researchers have studied the relationship between pretreatment serum levels of circulating HER2 ECD and response to hormone therapy in women with metastatic breast cancer [<a href="#rid26">26-32</a>]. However, results are inconclusive, and serum levels of circulating HER2 ECD should not guide choice of any therapy.</p><p class="headingAnchor" id="H1168367457"><span class="h2">Differences between the 2013 and 2018 ASCO/CAP guidelines</span><span class="headingEndMark"> — </span>Compared with the 2013 guideline, the 2018 guideline revised the approach to less common clinical scenarios observed when using a dual-probe ISH assay, specifically the following:</p><p class="bulletIndent1"><span class="glyph">●</span>If the <em>HER2</em>/CEP17 ratio is ≥2.0 and an average <em>HER2</em> copy number is &lt;4.0 signals/cell. (This previously was considered HER2-positive disease, per 2013 guidelines.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the <em>HER2</em>/CEP17 ratio is &lt;2.0 and the average <em>HER2</em> copy number is ≥6.0 signals/cell. (This previously was considered HER2-positive disease, per 2013 guidelines.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the <em>HER2</em>/CEP17 ratio is &lt;2.0 and an average <em>HER2</em> copy number is between ≥4.0 and &lt;6.0 signals/cell.</p><p></p><p>In each of these situations, further workup is necessary. The approach to these less common scenarios is described in the table (<a class="graphic graphic_table graphicRef118704" href="/z/d/graphic/118704.html" rel="external">table 2</a>). Alternative genomic tests are not recommended for routine use, as they have not been clinically validated.</p><p class="headingAnchor" id="H692158618"><span class="h1">HER2 STATUS AND PREDICTING TREATMENT RESPONSE</span><span class="headingEndMark"> — </span>The only HER2 test results that are known to predict benefit from <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> are immunohistochemistry (IHC) 3+ score or fluorescence in situ hybridization (FISH) ≥2 ratio [<a href="#rid33">33</a>]. The other "equivocal" findings on FISH (eg, single copy &gt;6, etc.) are of unknown value in predicting benefit from trastuzumab.</p><p><a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is available for patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'HER2-low tumors'</a>.)</p><p>However, we also note that the interobserver pathologist reproducibility of classifying lesions as "1+" versus "0" is poor and is likely inadequate to accurately predict benefit from a chemotherapeutic agent; further data are needed.</p><p>Those with non-HER2-overexpressing breast cancers experience no benefit from adjuvant <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>. In a randomized trial of 3270 women with invasive breast cancer and IHC score of 1+ or 2+ with FISH &lt;2 (or, if ratio was not performed, HER2 gene copy number &lt;4), the addition of trastuzumab to chemotherapy did not improve disease-free or overall survival [<a href="#rid33">33</a>].</p><p>In addition to predicting benefit from HER2-directed treatment, innumerable studies have examined HER2 expression as a predictor of benefit for other treatments for local and advanced breast cancer, including chemotherapy and endocrine therapy. However, the vast majority of these studies were done before the development of effective, anti-HER2 targeted drugs for early- (<a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>) and late-stage (trastuzumab, <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>, <a class="drug drug_general" data-topicid="88427" href="/z/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a>, <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a>) breast cancer. The importance of HER2 status for predicting use of non-HER2 therapies in the era of effective anti-HER2 treatments is less clear.</p><p class="bulletIndent1"><span class="glyph">●</span>Relevant discussion addressing the optimal chemotherapy regimen for those with early and metastatic HER2-positive tumors is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Choice of chemotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/106774.html" rel="external">"Neoadjuvant therapy for patients with HER2-positive breast cancer", section on 'Standard regimens'</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although several trials have concluded that patients with HER2-overexpressing tumors are relatively resistant to adjuvant hormone therapy [<a href="#rid34">34-39</a>], a similar number have failed to demonstrate such a relationship [<a href="#rid11">11,40-44</a>], and others even suggest a positive influence of HER2 overexpression on treatment response. As such, guidelines from an expert panel on tumor markers in breast cancer convened by the American Society of Clinical Oncology (ASCO) recommended that HER2 status not be used to withhold endocrine therapy for a patient with a hormone receptor-positive breast cancer, nor to select one specific type of endocrine therapy over another [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/98345.html" rel="external">"Neoadjuvant management of newly diagnosed hormone-positive breast cancer", section on 'Neoadjuvant endocrine therapy'</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Special considerations for hormone receptor-positive disease'</a>.)</p><p></p><p class="headingAnchor" id="H1076404098"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H178451157"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/877.html" rel="external">"Patient education: Treatment of early HER2-positive breast cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Amplification or overexpression of the human epidermal growth factor receptor 2 (<em>HER2</em>) oncogene is present in approximately 15 percent of primary invasive breast cancers. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for HER2 testing</strong> – We recommend routine testing of HER2 expression on newly diagnosed, invasive, and metastatic breast cancers. High levels of HER2 expression identify those women who benefit from treatment with agents that target HER2. (See <a class="local">'Clinical utility of HER2 testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidelines for HER2 testing</strong> – Guidelines for HER2 testing from a joint consensus panel of the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are provided (<a class="graphic graphic_table graphicRef75536" href="/z/d/graphic/75536.html" rel="external">table 1</a>). Although HER2 status is typically initially assessed by immunohistochemistry (IHC), we recommend confirmatory fluorescence in situ hybridization (FISH) testing for patients whose tumors are 2+ by IHC. (See <a class="local">'Testing for HER2 expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment implications</strong> – For patients with high levels of HER2 overexpression (IHC 3+; or <em>HER2</em>/CEP17 ratio on FISH ≥2.0 with average <em>HER2</em> copy number on FISH ≥4.0 signals/cell), we recommend administration of HER2-directed treatment in the adjuvant and/or metastatic setting (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Testing for HER2 expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to retest</strong> – Given the possibility of discordant HER2 expression from the primary and metastases, HER2 status should be reanalyzed in biopsies obtained from newly recurrent metastases, particularly if the primary tumor was negative or only weakly positive. (See <a class="local">'Situations in which to retest'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-HER2 therapy with chemotherapy</strong> – Relevant discussion addressing the optimal chemotherapy regimen for those with early and metastatic HER2-positive tumors is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Choice of chemotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/106774.html" rel="external">"Neoadjuvant therapy for patients with HER2-positive breast cancer", section on 'Standard regimens'</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of HER2 status in hormone receptor-positive cancers</strong> – HER2 status should not be used to withhold endocrine therapy for a patient with a hormone receptor-positive breast cancer, nor to select one specific type of endocrine therapy over another. (See <a class="local">'HER2 status and predicting treatment response'</a> above and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/98345.html" rel="external">"Neoadjuvant management of newly diagnosed hormone-positive breast cancer", section on 'Neoadjuvant endocrine therapy'</a> and  <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Special considerations for hormone receptor-positive disease'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229:974.</a></li><li><a class="nounderline abstract_t">Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999; 96:4995.</a></li><li><a class="nounderline abstract_t">Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15:254.</a></li><li><a class="nounderline abstract_t">Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523.</a></li><li><a class="nounderline abstract_t">Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 2004; 10:7972.</a></li><li><a class="nounderline abstract_t">Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008; 54:e1.</a></li><li><a class="nounderline abstract_t">Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008; 61:818.</a></li><li><a class="nounderline abstract_t">Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31:3997.</a></li><li class="breakAll">NCCN Clinical Practice Guideline in Oncology: Breast Cancer. Version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on June 15, 2017).</li><li><a class="nounderline abstract_t">Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36:2105.</a></li><li><a class="nounderline abstract_t">Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21:453.</a></li><li><a class="nounderline abstract_t">Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13:1036.</a></li><li><a class="nounderline abstract_t">Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103:1763.</a></li><li><a class="nounderline abstract_t">Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93:552.</a></li><li><a class="nounderline abstract_t">Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17:2055.</a></li><li><a class="nounderline abstract_t">Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101:9393.</a></li><li><a class="nounderline abstract_t">Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104:257.</a></li><li><a class="nounderline abstract_t">Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13:838.</a></li><li><a class="nounderline abstract_t">Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.</a></li><li><a class="nounderline abstract_t">Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:1618.</a></li><li><a class="nounderline abstract_t">Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005; 7:R436.</a></li><li><a class="nounderline abstract_t">Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005; 16:234.</a></li><li><a class="nounderline abstract_t">Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008; 113:1294.</a></li><li><a class="nounderline abstract_t">Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009; 27:1685.</a></li><li><a class="nounderline abstract_t">Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011; 12:286.</a></li><li><a class="nounderline abstract_t">Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13:1129.</a></li><li><a class="nounderline abstract_t">Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15:2518.</a></li><li><a class="nounderline abstract_t">Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21:1967.</a></li><li><a class="nounderline abstract_t">Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40:251.</a></li><li><a class="nounderline abstract_t">Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20:1467.</a></li><li><a class="nounderline abstract_t">Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7:2703.</a></li><li><a class="nounderline abstract_t">Colomer R, Llombart-Cussac A, Lloveras B, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007; 110:2178.</a></li><li><a class="nounderline abstract_t">Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol 2020; 38:444.</a></li><li><a class="nounderline abstract_t">Borg A, Baldetorp B, Fernö M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81:137.</a></li><li><a class="nounderline abstract_t">Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16:462.</a></li><li><a class="nounderline abstract_t">Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702.</a></li><li><a class="nounderline abstract_t">De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9:1039.</a></li><li><a class="nounderline abstract_t">Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808.</a></li><li><a class="nounderline abstract_t">De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11:4741.</a></li><li><a class="nounderline abstract_t">Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19:3376.</a></li><li><a class="nounderline abstract_t">Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18:3471.</a></li><li><a class="nounderline abstract_t">Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330:1253.</a></li><li><a class="nounderline abstract_t">Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90:1205.</a></li><li><a class="nounderline abstract_t">Stål O, Borg A, Fernö M, et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000; 11:1545.</a></li></ol></div><div id="topicVersionRevision">Topic 780 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2992089" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Amplification of a novel v-erbB-related gene in a human mammary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220407" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617201" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403702" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585632" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606634" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381380" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HER2 testing in the UK: further update to recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101045" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101045" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29846122" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560434" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176781" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15786420" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16106267" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307144" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194824" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HER-2 gene amplification can be acquired as breast cancer progresses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15952182" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650259" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954709" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15014012" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987448" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668276" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18661530" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255335" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376291" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738618" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215820" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743150" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883967" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prognostic significance of serum c-erbB-2 protein in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896093" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555582" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17926331" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31821109" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912163" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469329" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874330" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631604" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559718" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000569" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454885" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11032587" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080512" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9719081" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11205461" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
